Laura Rubio-Pérez

6PUBLICATIONS
69CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 27, 2025
Simultaneous secretion of a PD-L1 x 4-1BB bispecific antibody improves antileukemic efficacy of STAb-T cells secreting a CD19-specific T-cell engager.

Marina Gómez-Rosel, Laura Rubio-Pérez, Ivana Zagorac

|Mar 16, 2025
A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia.

Aïda Falgàs, Rodrigo Lázaro-Gorines, Samanta Romina Zanetti

|May 28, 2024
Characterization of a Trispecific PD-L1 Blocking Antibody That Exhibits EGFR-Conditional 4-1BB Agonist Activity.

Laura Rubio-Pérez, Susana Frago, Marta Compte

|Feb 14, 2024
Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo.

Laura Díez-Alonso, Aïda Falgas, Javier Arroyo-Ródenas

|Apr 28, 2023
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.

Laura Rubio-Pérez, Rodrigo Lázaro-Gorines, Seandean L Harwood

|Apr 01, 2022
Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.

Belén Blanco, Ángel Ramírez-Fernández, Clara Bueno

Pageof 1

Frequent Collaborators

6 joint publications

Luis Álvarez-Vallina

4 joint publications

Belén Blanco

4 joint publications

Marta Compte

4 joint publications

Carmen Domínguez-Alonso